Using natriuretic peptides to 'guide' therapy in heart failure

European Cardiology

Volumn 8, Issue 1, 2012, Pages 36-39

  van Kimmenade, Roland R J ^a   Januzzi, James L ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Biomarker; Natriuretic peptides; Prognosis; Therapy

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT;

ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR MORTALITY; CLINICAL PRACTICE; DISEASE SEVERITY; HEART EJECTION FRACTION; HEART FAILURE; HIGH RISK PATIENT; HUMAN; KINESIOTHERAPY; PRACTICE GUIDELINE; PROGNOSIS; QUALITY OF LIFE; RISK REDUCTION; TREATMENT PLANNING;

EID: 84871971327     PISSN: 17583756     EISSN: 17583764     Source Type: Journal    
DOI: 10.15420/ecr.2012.8.1.36     Document Type: Article

References (30)

1. Results of the Cooperative North Scandinavian enalapril survival study (CONSENSUS). The CONSENSUS trial study group, N Engl J Med, 1987;316:1429-35.
2. Pitt B, Segal R, Martinez FA, et al., Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of losartan in the elderly study, ELITE), Lancet, 1997;349:747-52.
3. The Cardiac insufficiency bisoprolol study II (CIBIS-II): A randomised trial, Lancet, 1999;353:9-13
4. Pitt B, Zannad F, Remme WJ, et al., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators, N Engl J Med, 1999;341:709-17.
5. Knight BP, Goyal R, Pelosi F, et al., Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator, J Am Coll Cardiol, 1999;33:1964-70.
6. Abraham WT, Fisher WG, Smith AL, et al., Cardiac resynchronization in chronic heart failure, N Engl J Med, 2002;346:1845-53.
7. Hunt SA, Abraham WT, Chin MH, et al., ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society, Circulation, 2005;112:e154-235.
8. Fonarow GC, Yancy CW, Albert NM, et al., Heart failure care in the outpatient cardiology practice setting: Findings from IMPROVE HF, Circ Heart Fail, 2008;1:98-106.
9. Januzzi JL Jr, Sakhuja R, O'Donoghue M, et al., Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department, Arch Intern Med, 2006;166:315-20.
10. Januzzi JL, van Kimmenade R, Lainchbury J, et al., NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: An international pooled analysis of 1256 patients: The international collaborative of NT-proBNP study, Eur Heart J, 2006;27:330-7.
11. Masson S, Latini R, Anand IS, et al., Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan heart failure trial), J Am Coll Cardiol, 2008;52:997-1003.
12. Troughton RW, Frampton CM, Yandle TG, et al., Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations, Lancet, 2000;355:1126-30.
13. Berger R, Moertl D, Peter S, et al., N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study, J Am Coll Cardiol, 2010;55:645-53.
14. Jourdain P, Jondeau G, Funck F, et al., Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: The STARS-BNP multicenter study, J Am Coll Cardiol, 2007;49:1733-9.
15. Januzzi JL Jr, Rehman SU, Mohammed AA, et al., Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction, J Am Coll Cardiol, 2011;58:1881-9.
16. Lainchbury JG, Troughton RW, Strangman KM, et al., N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: Results from the BATTLESCARRED (NT-proBNP-assisted treatment to lessen serial cardiac readmissions and death) trial, Am Coll Cardiol, 2009;55:53-60.
17. Persson H, Erntell H, Eriksson B, et al., Improved pharmacological therapy of chronic heart failure in primary care: A randomized study of NT-proBNP guided management of heart failure-SIGNAL-HF (Swedish intervention study-guidelines and NT-proBNP analysis in heart failure), Eur J Heart Fail, 2010;12:1300-8.
18. Pfisterer M, Buser P, Rickli H, et al., BNP-guided vs symptom-guided heart failure therapy: The trial of intensified vs standard medical therapy in elderly patients with congestive heart failure (TIME-CHF) randomized trial, JAMA, 2009;301:383-92.
19. Shah MR, Califf RM, Nohria A, et al., The STARBRITE trial: A randomized, pilot study of B-type natriuretic peptideguided therapy in patients with advanced heart failure, J Card Fail, 2011;17:613-21.
20. Eurlings LW, van Pol PE, Kok WE, et al., Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: Results of the PRIMA (can pro-brain-natriuretic peptide guided therapy of chronic heart failure improve heart failure morbidity and mortality?) study, J Am Coll Cardiol, 2010;56:2090-2100.
21. Karlstrom P, Alehagen U, Boman K, Dahlstrom U, Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: Responders to treatment have a significantly better outcome, Eur J Heart Fail, 2011;13:1096-1103
22. Felker GM, Hasselblad V, Hernandez AF, O'Connor CM, Biomarker-guided therapy in chronic heart failure: A meta-analysis of randomized controlled trials, Am Heart J, 2009;158:422-30
23. Porapakkham P, Zimmet H, Billah B, Krum H, B-type natriuretic peptide-guided heart failure therapy: A meta-analysis, Arch Intern Med, 2010;170:507-14
24. Braunschweig F, Fahrleitner-Pammer A, Mangiavacchi M, et al., Correlation between serial measurements of N-terminal pro brain natriuretic peptide and ambulatory cardiac filling pressures in outpatients with chronic heart failure, Eur J Heart Fail, 2006;8:797-803.
25. Kim HN, Januzzi JL Jr, Natriuretic peptide testing in heart failure, Circulation, 2011;123:2015-9
26. Wu AH, Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: The role of biologic variation in the interpretation of results, Am Heart J, 2006;152:828-34
27. Pascual-Figal DA, Domingo M, Casas T, et al., Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients, Eur Heart J, 2008; 29:1011-8.
28. Januzzi JL, personal communication, Boston MA, 2012
29. Masson S, Latini R, Anand IS, et al., Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: The Valsartan Heart Failure (Val-HeFT) data, Clin Chem, 2006;52:1528-38.
30. Testani JM, Cappola TP, Brensinger CM, et al., Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure, J Am Coll Cardiol, 2011;58:375-82.